Under the background of the continuous rebound of the global covid-19 epidemic, covid-19 detected the intensive release of the performance of listed companies, and a number of listed companies released the latest performance express to further clarify the growth situation.
Among them, foreign trade orders have generally increased significantly into common characteristics, but the industry competition has intensified, and the relevant listed companies are expanding the testing track.
Beijing Hotgen Biotech Co.Ltd(688068) profit increased nearly 19 times
On February 27, Beijing Hotgen Biotech Co.Ltd(688068) released a performance express, which showed that the company achieved an operating revenue of 5.372 billion yuan in 2021, an increase of 946.14% compared with the same period last year; The net profit attributable to the owners of the parent company was 2.193 billion yuan, an increase of 185681% compared with the same period last year; The basic earnings per share is 35.26 yuan / share.
Previously, the Beijing Hotgen Biotech Co.Ltd(688068) performance forecast predicted that the net profit realized last year would increase by 168465% to 199697% year-on-year, and the performance growth rate remained the “king of pre increase” in the epidemic detection sector; In contrast, the profit of this performance express is closer to the upper limit of the previous forecast. In addition, the company achieved a net profit of 717 million yuan in the fourth quarter of last year.
Beijing Hotgen Biotech Co.Ltd(688068) pointed out that the company’s performance increased significantly last year, mainly due to the development of the New Coronavirus 2019n-CoV antigen detection kit (anterior nasal cavity) and the New Coronavirus 2019n-CoV antigen detection kit (saliva) in the early 2021, and the two rapid detection reagent products of New Coronavirus antigen. Earlier obtained the certification of the German Federal Institute of drugs and medical devices (bfarm) for home free testing, which was applied to the local epidemic prevention demand in Germany, resulting in the explosive growth of the company’s foreign trade orders in the first half of the year; In the second half of this year, the self testing products of New Coronavirus developed by Beijing Hotgen Biotech Co.Ltd(688068) have obtained self testing registration and filing of EU CE and major economies such as MHRA, France ANSM and so on. In the fourth quarter, the COVID-19 virus epidemic in Europe, Southeast Asia and other countries was affected by the variation of COVID-19 virus Delta and the Olympic Games. With the substantial increase in the demand for covid-19 antigen testing products, the revenue of overseas covid-19 antigen testing products has increased significantly.
However, Beijing Hotgen Biotech Co.Ltd(688068) also suggests that there is some uncertainty whether the company’s future sales performance can continue to maintain a significant growth trend, which depends on the progress of global covid-19 epidemic prevention and control, the path selection of international epidemic for technical products, as well as the company’s product market competitiveness and channel ability.
Beijing Hotgen Biotech Co.Ltd(688068) is also strengthening the global strategic layout. On February 16, it was disclosed that it will invest US $5 million in New York state to establish a wholly-owned subsidiary, hot view health, so as to further meet the business development and nearby supporting needs in the Americas and other places and deeply expand overseas markets.
expand overseas markets
In addition to Beijing Hotgen Biotech Co.Ltd(688068) , a number of epidemic detection listed companies have disclosed the latest performance express. Foreign trade orders have become an important driving force driving growth, with varying degrees of influence, and said they will increase the overseas market.
Hangzhou Biotest Biotech Co.Ltd(688767) recently, the results showed that in 2021, the company’s total operating revenue doubled year-on-year to about 1.8 billion yuan, and the net profit attributable to the owner of the parent company was 833 million yuan, an increase of about 90% over the previous year.
Hangzhou Biotest Biotech Co.Ltd(688767) said that the covid-19 antigen family self-test kit of the company has successively obtained the EU CE certification and Australia TGA certification, which has promoted the surge in the number of foreign trade orders, resulting in a significant increase in the company’s operating performance compared with the same period last year.
In addition, Hangzhou Alltest Biotech Co.Ltd(688606) last year, it developed a series of covid-19 detection products such as covid-19 antigen (nasal swab) rapid detection and covid-19 antigen (saliva) rapid detection, and obtained covid-19 product registration certificates from Europe CE self-test, Australia TGA, Malaysia, Singapore and other countries, which promoted the steady growth of the company’s performance. In 2021 Hangzhou Alltest Biotech Co.Ltd(688606) last year, the operating revenue increased by nearly 70% year-on-year, and the net profit was 761 million yuan, an increase of 12.11% over the same period of the previous year. However, the basic earnings per share reached 15.07 yuan, a decrease of 10.4% year-on-year.
Zhejiang Orient Gene Biotech Co.Ltd(688298) also said that due to the impact of the global covid-19 pneumonia epidemic, there is a large demand for overseas testing. The company’s covid-19 testing reagents continue to be exported to the European market and achieved significant sales performance, which promoted the substantial growth of operating revenue. Last year, the company achieved a total operating revenue of more than 10 billion yuan, a year-on-year increase of 2 times, and a net profit of 4.777 billion yuan, a year-on-year increase of about 1.85 times.
Recently, Fang Jianqiu, the Zhejiang Orient Gene Biotech Co.Ltd(688298) chairman, and Fang Xiaoliang, the general manager, issued an open letter to all shareholders and employees, which introduced that the company’s overseas investment was smooth. Hengjian, a wholly-owned subsidiary located in Houston, has developed rapidly, and has basically formed a diversified development pattern of R & D, production, sales and third-party testing. The U.S. industrial base will also realize production and sales this year; The Vancouver subsidiary of Canada is developing steadily. Alco biotechnology company is newly established in Scotland, UK, which is mainly engaged in the production of covid-19 antigen, antibody and nucleic acid detection reagent. It is expected to be officially put into production and operation in about a month.
industry competition intensifies
With the normalization of epidemic prevention and control in China, the competition in the testing industry has intensified. According to insiders, on the whole, the demand for covid-19 nucleic acid testing services has decreased significantly year-on-year in 2020. With the superposition of the impact of centralized government procurement, the “simultaneous decline of volume and price” in China’s covid-19 nucleic acid testing market will become a trend.
Nanjing Vazyme Biotech Co.Ltd(688105) latest performance express shows that last year, the company achieved an operating revenue of 1.864 billion yuan, an increase of 19.13% over the same period last year, but a net profit of 678 million yuan, a decrease of 17.43% over the same period last year.
Nanjing Vazyme Biotech Co.Ltd(688105) business mainly includes life science, in vitro diagnosis and biomedicine. Among them, affected by the implementation of the centralized procurement policy of medical devices and the further intensification of industrial competition, the company moderately reduced the ex factory price of covid-19 testing related raw materials and end products during the reporting period. The sales revenue of covid-19 related businesses (including diagnostic raw materials and terminal testing agents) of the company reached about 1.146 billion yuan, a decrease of about 3% compared with the same period in 2020. In contrast, thanks to China’s covid-19 epidemic prevention policy, the business of the main customer groups of the company’s regular business has returned to normal and recovered in time.
In a recent institutional survey, Nanjing Vazyme Biotech Co.Ltd(688105) executives said that since 2019, the company has been testing the water with biological research reagent products to layout the overseas market. Up to now, the proportion of income from overseas business (including covid-19 related testing reagents) is still not high, so there is a certain room for improvement.
The company’s development plan in recent years will focus on the overseas market. At present, it has preliminarily established a systematic international business team, and stationed sales support and R & D support in Europe, Southeast Asia and other places.
At the same time, Nanjing Vazyme Biotech Co.Ltd(688105) company executives said that in combination with 2021 and the current global epidemic situation, it is expected that China and overseas will still maintain a certain amount of covid-19 nucleic acid detection during the reporting period; At present, the company’s antibody and antigen kits are mainly exported overseas, and the required overseas registration access has been obtained. Combined with the recent overseas epidemic, it is expected that the export of relevant testing reagents will still be sustainable.
In addition, Shanghai Zj Bio-Tech Co.Ltd(688317) performance changes are more obvious. The performance express shows that in 2021, the company achieved a revenue of 2.021 billion yuan, a year-on-year decrease of 1.52%; The net profit attributable to shareholders of listed companies was 764 million yuan, a year-on-year decrease of 18.07%. The company said that it was mainly due to the centralized collection of covid-19 virus detection reagents, which led to the decline of the gross profit of the company’s corresponding products. In addition, the company increased market development and R & D efforts, and the corresponding cost increased.
It is understood that the covid-19 epidemic broke out in 2020, and Shanghai Zj Bio-Tech Co.Ltd(688317) successfully developed covid-19 virus nucleic acid detection reagent, becoming the first batch of enterprises in China to obtain the registration certificate of covid-19 virus nucleic acid detection reagent; Since then, the company’s covid-19 virus nucleic acid detection reagent has successively obtained EU CE certification and Australian drug administration (TGA) certification, and has been listed in the WHO emergency use list.
In the survey conducted by the organization in January, Shanghai Zj Bio-Tech Co.Ltd(688317) executives said that the overseas market is in short supply as a whole, and the companies in the overseas market have been developing and have formed a relatively stable sales channel. At present, the feedback from overseas cooperation channel providers is still relatively positive. The registration and declaration of the United States is in progress, and the promotion is accelerated in countries and regions that recognize the EU CE.
In contrast, in the Chinese market, Shanghai Zj Bio-Tech Co.Ltd(688317) executives pointed out that after several times of national centralized procurement, the reagent price has decreased a lot; Now the price of nucleic acid detection is basically balanced, and the volume is enlarged, which can ensure the stability of performance. In addition, the fermentation of covid-19 epidemic has attracted many molecular testing companies, and the testing reagent track is becoming more and more crowded. Head effect is still obvious, Shanghai Zj Bio-Tech Co.Ltd(688317) on the one hand, internal cost control and quality control can be carried out, and at the same time, more new products can be developed as much as possible to improve competitiveness.
